MiniMed Group (NASDAQ:MMED) Stock Price Expected to Rise, Bank of America Analyst Says

MiniMed Group (NASDAQ:MMED) had its price target boosted by stock analysts at Bank of America from $24.00 to $28.00 in a report released on Wednesday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. Bank of America‘s price target would suggest a potential upside of 24.89% from the stock’s current price.

MMED has been the subject of a number of other reports. UBS Group started coverage on shares of MiniMed Group in a research note on Tuesday, July 28th. They issued a “buy” rating and a $25.00 target price for the company. BTIG Research raised their price target on shares of MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday. Weiss Ratings upgraded shares of MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Wells Fargo & Company reduced their price objective on MiniMed Group from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $16.00 price objective on shares of MiniMed Group in a research report on Thursday, June 4th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.46.

MiniMed Group Price Performance

MMED stock opened at $22.42 on Wednesday. The firm has a market cap of $6.31 billion and a PE ratio of -32.97. The company’s fifty day simple moving average is $17.65. MiniMed Group has a fifty-two week low of $10.65 and a fifty-two week high of $22.74.

MiniMed Group (NASDAQ:MMED) last announced its earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The firm had revenue of $837.00 million during the quarter. The firm’s revenue for the quarter was up 15.6% on a year-over-year basis. As a group, equities research analysts forecast that MiniMed Group will post 0.66 earnings per share for the current year.

Institutional Investors Weigh In On MiniMed Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in MMED. BlackRock Inc. boosted its stake in shares of MiniMed Group by 7,527.5% during the 2nd quarter. BlackRock Inc. now owns 1,996,489 shares of the company’s stock worth $29,848,000 after buying an additional 1,970,314 shares during the last quarter. J. Goldman & Co LP acquired a new stake in shares of MiniMed Group in the second quarter valued at about $12,412,000. Readystate Asset Management LP acquired a new position in MiniMed Group during the second quarter valued at approximately $4,400,000. Bank of America Corp DE grew its stake in MiniMed Group by 377.0% in the second quarter. Bank of America Corp DE now owns 238,819 shares of the company’s stock valued at $3,570,000 after purchasing an additional 188,756 shares in the last quarter. Finally, Freestone Grove Partners LP bought a new position in MiniMed Group in the second quarter valued at approximately $1,745,000.

MiniMed Group News Summary

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 2027 net sales of $843 million, up 17% year over year, with organic U.S. sales growth accelerating to 13% and international sales rising 18% as reported. Earnings per share also exceeded analyst expectations. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Management raised its fiscal 2027 organic revenue-growth guidance, signaling confidence that recent momentum can continue. The company also said its product pipeline is progressing ahead of schedule, including FDA submission plans for MiniMed Fit™, CE Mark progress for MiniMed Flex™, completion of enrollment in the Vivera™ FCL U.S. pivotal trial, and IDE approval for a next-generation extended-wear sensor. MiniMed Group Releases Q1 2027 Financial Results
• Positive Sentiment: BTIG Research raised its price target to $28 from $25 and maintained a “buy” rating, reflecting expectations for further upside based on the company’s growth outlook. MiniMed Group Price Target Increase
• Neutral Sentiment: The earnings call highlighted the quarter’s performance and pipeline developments, giving investors additional detail on the company’s operating outlook. MiniMed Group Q1 2027 Earnings Call Transcript
• Negative Sentiment: The consensus broker price target is $21.62, below the stock’s recent quoted level, suggesting that some analysts see limited near-term upside despite the improved operating results. MiniMed Group Receives Consensus Target Price

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.